Glenmark Pharmaceuticals Limited has informed the Exchange about press release dated 20-Oct-2022 titled Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities.